These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. The rise of European venture capital for biotechnology. Howell M; Trull M; Dibner MD Nat Biotechnol; 2003 Nov; 21(11):1287-91. PubMed ID: 14595356 [No Abstract] [Full Text] [Related]
9. IPO plans sour on both sides of the pond. Mitchell P Nat Biotechnol; 2004 Aug; 22(8):929-30. PubMed ID: 15286629 [No Abstract] [Full Text] [Related]
11. IPOs: the narrow window closes? Lawrence S Nat Biotechnol; 2004 Dec; 22(12):1489. PubMed ID: 15583641 [No Abstract] [Full Text] [Related]
12. Biotech IPOs--flop or pop? Jacobs T Nat Biotechnol; 2004 Aug; 22(8):949. PubMed ID: 15286641 [No Abstract] [Full Text] [Related]
13. Biotech financing retrenches in Q2. Lawrence S Nat Biotechnol; 2006 Aug; 24(8):883. PubMed ID: 16900116 [No Abstract] [Full Text] [Related]
14. Looking at US versus European exit opportunities. Lawrence S Nat Biotechnol; 2005 Oct; 23(10):1203. PubMed ID: 16302294 [No Abstract] [Full Text] [Related]
15. Mind the (biomedical funding) gap. Klausner A Nat Biotechnol; 2005 Oct; 23(10):1217-8. PubMed ID: 16211055 [No Abstract] [Full Text] [Related]
16. Mixed results in Q1. Lawrence S Nat Biotechnol; 2005 May; 23(5):518. PubMed ID: 15877059 [No Abstract] [Full Text] [Related]
18. Biotechs await single European financial market. Louët S Nat Biotechnol; 2003 Dec; 21(12):1417. PubMed ID: 14647312 [No Abstract] [Full Text] [Related]
19. Biotechnology financing dilemmas and the role of special purpose entities. Schiff L; Murray F Nat Biotechnol; 2004 Mar; 22(3):271-7. PubMed ID: 14990945 [No Abstract] [Full Text] [Related]
20. Korean biotechs seize opportunity to list on public markets. Louët S Nat Biotechnol; 2005 Oct; 23(10):1189-90. PubMed ID: 16211042 [No Abstract] [Full Text] [Related] [Next] [New Search]